Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Get Shukra Pharmaceuticals Ltd's next results in your feed
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Shukra Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- For the quarter ended September 30, 2026, revenue from operations is ₹4,420.38 Lakhs compared to ₹587.74 Lakhs for the quarter ended September 30, 2025.
As stated in Shukra Pharmaceuticals Ltd's Q2 FY27 results statement · published 5 Nov 2026. Reported figures, not investment advice.
Based on Shukra Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
For the quarter ended September 30, 2026, revenue from operations is ₹4,420.38 Lakhs compared to ₹587.74 Lakhs for the quarter ended September 30, 2025. Quarter ended September 30, 2026:.
From Shukra Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.
How did Shukra Pharmaceuticals' revenue grow in the September 2026 quarter?
- For the quarter ended September 30, 2026, revenue from operations is ₹4,420.38 Lakhs compared to ₹587.74 Lakhs for the quarter ended September 30, 2025.
- This represents a significant year-on-year increase in revenue.
- The consolidated financials show total income from operations for the quarter as ₹4,477.58 Lakhs (September 30, 2026) versus ₹759.00 Lakhs for the same quarter in 2025, confirming strong growth.
- The focus is on reporting current and past financial results rather than projecting future sales or volumes.
What happened to Shukra Pharmaceuticals' margins in Q2 FY27?
See what Shukra Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
What capex is Shukra Pharmaceuticals planning?
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Shukra Pharmaceuticals raising money or cutting debt?
See what Shukra Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Shukra Pharmaceuticals' order book?
Shukra Pharmaceuticals Ltd — Quarterly revenue & net profit
Shukra Pharmaceuticals Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 44 |
| Operating profit (EBITDA) | 19 |
| Operating margin | 42.3% |
| Profit before tax | 18 |
| Net profit (PAT) | 13 |
| EPS (₹) | 0.29 |
Source: Shukra Pharmaceuticals Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹44 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Shilpa Medicare Ltd (Q2 FY27)
2QFY27 total revenue: INR 538 cr, up 45% YoY (from INR 372 cr in 2QFY26). Key investor presentation takeaways from Shilpa Medicare Ltd's Q2 FY27 investor presen
- Wanbury (Q2 FY27)
Revenue from operations for the quarter ended 30 September 2026 is ₹18,290.97 Lakhs (₹182.91 Crores). Key results statement takeaways from Wanbury Ltd's Q2 FY27
- Influx Healthtech (Q2 FY27)
Revenue from operations for H1 FY27: ₹85.4 crores . Key investor presentation takeaways from Influx Healthtech Ltd's Q2 FY27 investor presentation — and how it
- Unichem Laboratories (Q2 FY27)
Revenue from operations for the quarter ended 30.09.2026 is ₹401.90 crores (standalone) and ₹640.22 crores (consolidated). Key results statement takeaways from
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Shukra Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Shukra Pharmaceuticals Ltd Q2 FY27 results?
For the quarter ended September 30, 2026, revenue from operations is ₹4,420.38 Lakhs compared to ₹587.74 Lakhs for the quarter ended September 30, 2025. Quarter ended September 30, 2026:.
What is Shukra Pharmaceuticals Ltd share price analysis?
Shukra Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 98.1 with a market cap of ₹3,534 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Shukra Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.